<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780972</url>
  </required_header>
  <id_info>
    <org_study_id>ONL1204-RRD-001</org_study_id>
    <nct_id>NCT03780972</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment</brief_title>
  <official_title>A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ONL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ONL Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ONL1204 in&#xD;
      participants with Macula-off, Rhegmatogenous Retinal Detachment (RRD). RRD is an acute and&#xD;
      serious vision threatening condition in which a tear in the retina, typically resulting from&#xD;
      a vitreous detachment, allows liquid to accumulate under the retina, detaching the&#xD;
      photoreceptor (PR) layer of the retina from the retinal pigment epithelium (RPE). As the RPE&#xD;
      is the principal source of nutritional support for the PR layer, the photoreceptors begin a&#xD;
      cascade of inflammation and cell death. Photoreceptor cell death is the primary mechanism of&#xD;
      vision loss after retinal detachment.&#xD;
&#xD;
      ONL1204 is a first-in-class inhibitor of Fragment Apoptosis Stimulator receptor&#xD;
      (Fas)-mediated cell death. ONL1204 has demonstrated protection of multiple retinal cell types&#xD;
      in numerous preclinical models of acute ocular injury. This will be a first-in-human (FIH)&#xD;
      study to evaluate safety and tolerability of a single-dose of ONL1204 in participants with&#xD;
      macula-off RRD. The standard of care for surgical repair of macula-off RRD is reattachment&#xD;
      surgery within 7 days of the macula detaching. Participants in this study will receive a&#xD;
      single intravitreal injection upon diagnosis and enrollment in the study, followed by&#xD;
      standard of care surgery. The surgery includes vitrectomy, a procedure that removes the bulk&#xD;
      of drug remaining in the vitreous.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital sign-systolic and diastolic blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Systolic and diastolic blood pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign-heart rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Heart rate in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>24 weeks</time_frame>
    <description>ETDRS chart (number of letters read)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Intraocular pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit lamp biomicroscopy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Slit lamp biomicroscopy (using US FDA clinical grading scale 0-4; 0=normal, 4=very severe changes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>24 weeks</time_frame>
    <description>White blood cells with differential, hemoglobin, hematocrit and platelet count</description>
  </primary_outcome>
  <other_outcome>
    <measure>Exploratory outcome-ONL1204 concentration</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measurement of ONL1204 in plasma (ng/ml) after drug administration</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Rhegmatogenous Retinal Detachment - Macula Off</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Dose B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Dose C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Dose D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONL1204</intervention_name>
    <description>Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection</description>
    <arm_group_label>Cohort 1 Dose A</arm_group_label>
    <arm_group_label>Cohort 2 Dose B</arm_group_label>
    <arm_group_label>Cohort 3 Dose C</arm_group_label>
    <arm_group_label>Cohort 4 Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal Injection</intervention_name>
    <description>Injection of study drug into the eye</description>
    <arm_group_label>Cohort 1 Dose A</arm_group_label>
    <arm_group_label>Cohort 2 Dose B</arm_group_label>
    <arm_group_label>Cohort 3 Dose C</arm_group_label>
    <arm_group_label>Cohort 4 Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of ocular fluids</intervention_name>
    <description>vitreous and aqueous fluid collection by a tap and during vitrectomy</description>
    <arm_group_label>Cohort 1 Dose A</arm_group_label>
    <arm_group_label>Cohort 2 Dose B</arm_group_label>
    <arm_group_label>Cohort 3 Dose C</arm_group_label>
    <arm_group_label>Cohort 4 Dose D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, ≥ 18 to 80 years old&#xD;
&#xD;
          2. Able to give informed consent and comply with all study visits and procedures&#xD;
&#xD;
          3. Patients who:&#xD;
&#xD;
               1. Present between 1 week (7 days) and 4 weeks (28 days) of a macula-off RRD (based&#xD;
                  on patient-reported history of loss of central vision)&#xD;
&#xD;
               2. For whom standard retinal reattachment surgery by means of a pars plana&#xD;
                  vitrectomy (with or without scleral buckle) and gas tamponade is indicated, and&#xD;
&#xD;
               3. In the opinion of the investigator, can safely undergo all study procedures.&#xD;
&#xD;
          4. Best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of&#xD;
             20/100 to hand motion in the study eye&#xD;
&#xD;
          5. Best corrected ETDRS visual acuity in the fellow eye of 20/60 or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of giant retinal tear defined as greater than 3 clock hours or other type of&#xD;
             complex retinal detachment in the study eye&#xD;
&#xD;
          2. Presence of vitreous hemorrhage in the study eye&#xD;
&#xD;
          3. Presence of ocular or periocular infection or intraocular inflammation in either eye&#xD;
&#xD;
          4. Intraocular Pressure &gt; 22 mmHg in the study eye&#xD;
&#xD;
          5. Any other significant ocular disease in the study eye including media opacity that, in&#xD;
             the opinion of the investigator, would preclude a visual acuity of at least 20/25&#xD;
             following successful vitrectomy or limit adequate visibility of the retina&#xD;
&#xD;
          6. Any other ocular pathology in the study eye requiring treatment with topical&#xD;
             ophthalmic drops or intravitreal injection&#xD;
&#xD;
          7. History of previous ocular surgery in the study eye other than uncomplicated cataract&#xD;
             surgery with posterior chamber intraocular lens and intact posterior capsule (which&#xD;
             must have occurred at least 6 months prior to the baseline visit)&#xD;
&#xD;
          8. Participation in other clinical trials or use of any other investigational drugs or&#xD;
             devices within 3 months prior to study participation&#xD;
&#xD;
          9. Females who are pregnant or lactating and women of childbearing potential who are not&#xD;
             using adequate contraceptive precautions (e.g., intrauterine device, oral&#xD;
             contraceptives, barrier method, or other contraception deemed adequate by the&#xD;
             investigator)&#xD;
&#xD;
         10. Known retinopathy, known hepatic disease (or history of significant chronic liver&#xD;
             disease), or known renal disease. Patients with diabetes and no known retinopathy may&#xD;
             be enrolled&#xD;
&#xD;
         11. History of uncontrolled hypertension&#xD;
&#xD;
         12. History of stroke, transient ischemic attack, or major cardiac surgery within 3 months&#xD;
             prior to study, or current treatment for systemic infection&#xD;
&#xD;
         13. Any ocular or systemic condition that in the opinion of the investigator could&#xD;
             compromise the safety of the patient, or may interfere with the safety and&#xD;
             tolerability assessments or study procedures of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Simunovic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Save Sight Institute, Sydney Eye Hospital, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana van de Goor, Ph.D.</last_name>
    <phone>650-303-0094</phone>
    <email>jvandegoor@onltherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Zacks, M.D./Ph.D.</last_name>
    <phone>734-936-0871</phone>
    <email>dnzacks@onltherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Save Sight Institute, Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Simunovic, M.D.</last_name>
      <phone>+61 2 9382 7300</phone>
    </contact>
    <contact_backup>
      <last_name>Maria Williams</last_name>
      <phone>+61 2 9382 7300</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

